In depth analysis of the HIV reservoir confirms effectiveness and safety of DTG/3TC in a phase 4 randomized controlled switch trial (RUMBA)

Reducing the number of active compounds for lifelong HIV treatment is of interest, especially to reduce potential long-term side effects. So far, available data assessing viral control, support the robustness and safety of 2DR (2-drug regimen) ART compared to 3DR. However, further in-depth investiga...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2024-09
Main Authors: De Scheerder, Marie-Angélique, Degroote, Sophie, Delporte, Mareva, Kiselinova, Maja, Trypsteen, Wim, Vincke, Lara, De Smet, Evelien, Van Den Eeckhout, Bram, Schrooyen, Loïc, Verschoore, Maxime, Muccini, Camilla, Vanherrewege, Sophie, Caluwe, Els, De Buyser, Stefanie, Gerlo, Sarah, Blomme, Evy, Vandekerckhove, Linos
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reducing the number of active compounds for lifelong HIV treatment is of interest, especially to reduce potential long-term side effects. So far, available data assessing viral control, support the robustness and safety of 2DR (2-drug regimen) ART compared to 3DR. However, further in-depth investigations of the viral reservoirs are mandatory to guarantee long-term safety of these regimens regarding stable intact HIV-1 DNA copies, HIV-1 RNA transcripts and sustained immunological control. The Rumba study is the first prospective randomized controlled trial evaluating the impact of switch from 3DR to 2DR on the viral reservoir. Participants on any stable 2nd generation INSTI-based 3DR regimen with HIV-1 RNA
ISSN:1537-6613
1537-6613
DOI:10.1093/infdis/jiae405